U.S., June 13 -- ClinicalTrials.gov registry received information related to the study (NCT07645755) titled 'CRETA (Clopidogrel Responsiveness in Essential ThrombocithemiA)' on June 09.
Brief Summary: Essential thrombocythemia (ET) is a chronic myeloproliferative neoplasm associated with increased platelet production and activation, leading to a high risk of thrombotic complications. Low-dose aspirin is the standard antiplatelet therapy for thrombosis prevention; however, the accelerated platelet turnover characteristic of ET results in rapid recovery of platelet function, making once-daily aspirin insufficient in many patients. Consequently, twice-daily low-dose aspirin is currently recommended to achieve adequate and sustained platelet i...